In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas
  
BioVersys and Shionogi will partner on antimicrobials for multiple-drug resistant pathogens (Shutterstock)

More from Deals

More from Business